Simvastatin interactions with other drugs

Bibliography

• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm [Last accessed 26 December 2011]
   Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006;26:1601-7
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
   PubMed Web of Science ®Google Scholar
• Xia CQ, Yang JJ, Gan LS. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005;1:595-611
   PubMed Web of Science ®Google Scholar
• Takeda M, Noshiro R, Onozato ML, Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 2004;483:133-8
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
   PubMed Web of Science ®Google Scholar
• Fernandez G, Spatz ES, Jablecki C, Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403
   PubMedGoogle Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52-60
   PubMed Web of Science ®Google Scholar
• Backman JT, Kyrklund C, Kivisto KT, Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Zhao JJ, Ma B, Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004;94:1140-6
   PubMed Web of Science ®Google Scholar
• Armitage J, Bowman L, Wallendszus K, Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69
   PubMed Web of Science ®Google Scholar
• Lasocki A, Vote B, Fassett R, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul Immunol Inflamm 2007;15:345-6
   PubMed Web of Science ®Google Scholar
• Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol 2003;10:172-4
   PubMedGoogle Scholar
• Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39:307-12
   PubMed Web of Science ®Google Scholar
• Cheng CH, Miller C, Lowe C, Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002;59:728-30
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm [Last accessed 26 December 2011]
   Google Scholar
• Mousa O, Brater DC, Sunblad KJ, The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-74
   PubMed Web of Science ®Google Scholar
• Kanathur N, Mathai MG, Byrd RP Jr, Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-41
   PubMedGoogle Scholar
• Hu M, Mak VW, Tomlinson B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J Clin Pharm Ther 2011;36:419-25
   PubMed Web of Science ®Google Scholar
• Nishio S, Watanabe H, Kosuge K, Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005;28:223-7
   PubMed Web of Science ®Google Scholar
• Park CG, Lee H, Choi JW, Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther 2010;48:497-503
   PubMed Web of Science ®Google Scholar
• Marot A, Morelle J, Chouinard VA, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2011;66:134-6
   PubMed Web of Science ®Google Scholar
• Jerling M, Huan BL, Leung K, Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33
   PubMed Web of Science ®Google Scholar
• Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health Syst Pharm 2010;67:1829-31
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101:915-25
   PubMed Web of Science ®Google Scholar
• Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 2006;12:1271-80
   PubMed Web of Science ®Google Scholar
• Gulec S, Ozdol C, Rahimov U, Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction. J Invasive Cardiol 2005;17:589-93
   PubMedGoogle Scholar
• Serrano Junior CV, Soeiro Ade M, Araujo LF, Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation. Arq Bras Cardiol 2010;95:321-7
   PubMed Web of Science ®Google Scholar
• Saw J, Brennan DM, Steinhubl SR, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5
   PubMed Web of Science ®Google Scholar
• Giorgi MA, Di Girolamo G, Gonzalez CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 2010;11:2391-403
   PubMed Web of Science ®Google Scholar
• Brilique, INN-ticagrelor. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct Information/human/001241/WC500100494.pdf [Last accessed 18 December 2011]
   Google Scholar
• Burtenshaw AJ, Sellors G, Downing R. Presumed interaction of fusidic acid with simvastatin. Anaesthesia 2008;63:656-8
   PubMed Web of Science ®Google Scholar
• Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol 2009;16:e78-9
   PubMedGoogle Scholar
• Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003;96:1034-5
   PubMed Web of Science ®Google Scholar
• Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008;9:232-4
   PubMed Web of Science ®Google Scholar
• Dopazo C, Bilbao I, Lazaro JL, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc 2009;41:1021-4
   PubMed Web of Science ®Google Scholar
• Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007;41:1292-5
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Dole K, He YL, Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23:2913-20
   PubMed Web of Science ®Google Scholar
• Krishna R, Garg A, Jin B, Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;67:520-6
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Phelan M, Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010;50:1188-201
   PubMed Web of Science ®Google Scholar
• Yu RZ, Geary RS, Flaim JD, Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48:39-50
   PubMed Web of Science ®Google Scholar